welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
PTC Therapeutics Announces First-Ever Winners of Its PRIORITY Program To Support Research Projects In Rare, Genetic Disorders
PTC Therapeutics, Inc. today announced the three funding recipients from PRIORITY, an annual program to support outstanding clinical research by the rare genetic disorders community. This year’s funding will accelerate innovative research projects to improve Duchenne muscular dystrophy screening in infants and support earlier diagnosis of this progressive, muscle-wasting disease.
“We were overwhelmed to receive so many outstanding applications in the first year of PRIORITY and to see such a breadth of ideas to improve the screening and diagnosis of Duchenne,” said Dr. Claudio Santos, Senior Vice President, Global Medical Affairs, PTC Therapeutics, Inc. “We are thrilled that the PRIORITY program will help bring these research projects to fruition and ultimately help patients receive the best care as early as possible.”
rareRelated
-
Coalition DuchenneThe mission of Coalition Duchenne is to ...
-
An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular DystrophyThe main objective of this study is to e...
-
Tamoxifen in Duchenne Muscular DystrophyA randomised, double blind, placebo cont...
-
ReveraGen Announces First Patient Enrollment in International Pivotal Trial of Vamorolone in Duchenne Muscular Dystr...ReveraGen BioPharma, Inc. today announce...
-
Statement from FDA Commissioner Scott Gottlieb, M.D. on agency’s efforts to advance development of gene therapiesOnce just a theory, gene therapies are n...
-
Phase IIb Study of PRO045 in Subjects With Duchenne Muscular DystrophyThe purpose of the study is to see wheth...
-
Future Clinical And Biomarker Development For SMT C1100, The First Utrophin Modulator To Enter Clinical Trials For D...Objective: To progress SMT C1100, Summi...
-
Edasalonexent could reduce functional decline in boys with DMD, MoveDMD phase 2 results suggestResults of the Phase 2 MoveDMD trial sho...
